Medlinker
Total Raised
$764.74MInvestors Count
10Deal Terms
6Investments
3Funding, Valuation & Revenue
6 Fundings
Medlinker has raised $764.74M over 6 rounds.
Medlinker's latest funding round was a Series E for $514M on December 13, 2021.
Medlinker's valuation in July 2018 was $1,000M.
Medlinker's latest post-money valuation is from December 2021.
Sign up for a free demo to see Medlinker's valuations in December 2021, December 2017, September 2015, February 2015 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/13/2021 | Series E | $514M | 3 | |||
7/31/2018 | Series D | ▲$1,000M | ||||
12/6/2017 | Series C | |||||
9/7/2015 | Series B | |||||
2/1/2015 | Series A |
Date | 12/13/2021 | 7/31/2018 | 12/6/2017 | 9/7/2015 | 2/1/2015 |
|---|---|---|---|---|---|
Round | Series E | Series D | Series C | Series B | Series A |
Amount | $514M | ||||
Investors | |||||
Valuation | ▲$1,000M | ||||
Revenue | |||||
Sources | 3 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Medlinker Deal Terms
6 Deal Terms
Medlinker's deal structure is available for 6 funding rounds, including their Series E from December 13, 2021.
Round | Series E | Series D | Series C | Series B | Series A |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series E | |||||||||||||||
Series D | |||||||||||||||
Series C | |||||||||||||||
Series B | |||||||||||||||
Series A |
Medlinker Investors
10 Investors
Medlinker has 10 investors. Sino Biopharmaceutical invested in Medlinker's Series E funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
12/13/2021 | 12/13/2021 | 1 Series E | Corporation | China | ||
2/1/2015 | 7/31/2018 | 3 Series A, Series C (2017), Series D (2018) | Venture Capital | China | ||
12/6/2017 | 7/31/2018 | 2 Series C, Series D (2018) | Investment Bank | China | ||
Asset/Investment Management | Hong Kong | |||||
Other |
First funding | 12/13/2021 | 2/1/2015 | 12/6/2017 | ||
|---|---|---|---|---|---|
Last Funding | 12/13/2021 | 7/31/2018 | 7/31/2018 | ||
Investor | |||||
Rounds | 1 Series E | 3 Series A, Series C (2017), Series D (2018) | 2 Series C, Series D (2018) | ||
Board Seats | |||||
Type | Corporation | Venture Capital | Investment Bank | Asset/Investment Management | Other |
Location | China | China | China | Hong Kong |
Medlinker Acquisitions
1 Acquisition
Medlinker acquired 1 company. Their latest acquisition was Tencent Doctorwork on December 14, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/14/2021 | Series A | $250M | Merger - II | 1 |
Date | 12/14/2021 |
|---|---|
Investment Stage | Series A |
Companies | |
Valuation | |
Total Funding | $250M |
Note | Merger - II |
Sources | 1 |
Medlinker Investments
3 Investments
Medlinker has made 3 investments. Their latest investment was in PSYAI as part of their Seed VC on August 06, 2021.
Medlinker Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
8/6/2021 | Seed VC | PSYAI | Yes | 1 | ||
2/22/2021 | Series A | |||||
3/30/2020 | Seed |
Date | 8/6/2021 | 2/22/2021 | 3/30/2020 |
|---|---|---|---|
Round | Seed VC | Series A | Seed |
Company | PSYAI | ||
Amount | |||
New? | Yes | ||
Co-Investors | |||
Sources | 1 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Medlinker to Competitors
ABC Clinic Manager is a company that specializes in digital healthcare solutions, operating in the healthcare technology sector. The company offers a comprehensive clinic management system that includes features for appointment scheduling, electronic medical records, medication management, patient management, and chain clinic management. The system is designed to assist various types of clinics and healthcare institutions in improving their operational efficiency. It was founded in 2017 and is based in Chengdu, Sichuan.
Justhealth develops artificial intelligence (AI) based healthcare software. The company aims to achieve post-diagnosis disease management and service operations. The company serves chemicals, food, pharmaceutical, and agriculture. It was founded in 2015 and is based in Hangzhou, China.
Yidu Technology specializes in AI and big data-driven digital transformation for the healthcare industry. The company offers data analysis and evidence-based decision-making solutions to improve efficiency and accessibility in healthcare, and constructs a medical ecosystem that reduces information asymmetry among industry participants. Yidu Technology primarily serves various sectors including hospitals, insurance companies, life science organizations, research institutions, and regulatory bodies. It was founded in 2014 and is based in Beijing, Beijing.
Jingli Technology is a company focused on digital health services in the healthcare and retail sectors. The company offers digital services and intelligent product tools based on evidence-based medicine, aiming to provide excellent health products and services that meet user needs. Jingli Technology primarily serves the medical and consumer retail industries. It is based in Shanghai, Shanghai.
Lachesis is committed to the establishment of medical big data through the collection, screening, and integration of clinical data. It provides intelligent decision-making and intelligent nursing for clinical diagnosis and treatment.
Taimei Technology operates as a digital operation platform. It is a software-as-a-service (SaaS) provider that has developed the MobileMD System, with products including clinical research data collection system eCollect, randomized grouping and drug management system eBalance, and patients report system eReport. Its business covers pharmaceutical research and development, pharmacovigilance, pharmaceutical marketing and market access, and other fields. The company was founded in 2013 and is based in Jiaxing, China.
Loading...